In this article, we take a look at 10 Potential Takeover Targets with Strong Price Momentum.

Takeover speculation is getting more attention because the broader deal backdrop has improved, even if activity remains selective rather than indiscriminate. Reuters, citing LSEG data, reported that global M&A volume reached $4.6 trillion in 2025, up 49% from 2024, and that the first quarter of 2026 alone topped $1.2 trillion in deal value, up 26% from a year earlier.

Private capital also remains a meaningful force behind the theme. PitchBook said that closed-end private capital funds globally held $4.63 trillion in dry powder as of the end of the second quarter of 2025, while Reuters reported that bankers and M&A lawyers entered 2026 expecting private equity to remain active in larger transactions.

That backdrop has started to show up in stock prices recently. Brown-Forman rose nearly 15% after reports that Sazerac had approached the company while Pernod Ricard was already in talks, and Commvault jumped more than 17% after Reuters reported it was exploring a sale following takeover interest.

That helps explain why potential takeover targets are appearing across different industries rather than clustering in one corner of the market. In many cases, the momentum is not purely technical. It is being reinforced, at least partly, by credible strategic interest, strategic reviews, or the market’s attempt to price in optionality before any deal is signed.

Methodology

For this list, we identified potential takeover targets by combining two factors: credible merger or acquisition interest and sustained price momentum. Companies were selected based on recent reports of strategic reviews, takeover approaches, or activist-driven pressure to divest from sources such as Reuters and Bloomberg. Price momentum was assessed over a multi-week to multi-month period to avoid short-term volatility driven by unsubstantiated rumors. These stocks are also popular among Wall Street analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Revolution Medicines, Inc. (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the 10 potential takeover targets with strong price momentum. The appeal is not hard to see. The company is built around RAS-targeted oncology, and their daraxonrasib has become one of the most closely watched assets in that space.

The stock’s momentum has only strengthened the strategic case. Barron’s reported on April 13 that Revolution Medicines shares had already gained 164% over the prior year before jumping another 39% that day after new trial data. The catalyst was daraxonrasib’s pivotal Phase 3 RASolute 302 result announced on April 13, 2026. Reuters reported that the drug helped previously treated metastatic pancreatic cancer patients live a median of 13.2 months, compared with 6.7 months for standard chemotherapy, while also improving progression-free survival. RBC said the drug could eventually generate more than $5 billion in U.S. sales.

Daraxonrasib’s strategic value had already drawn takeover attention. On January 8, 2026, Reuters reported that Merck was in talks to buy Revolution Medicines in a deal that could value the company at $28 billion to $32 billion. Earlier, the Wall Street Journal had reported AbbVie was near a deal, though AbbVie denied it to Reuters the next day. Later in January, Reuters reported that Merck was no longer in talks, but said another buyer could still emerge.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a late-stage clinical oncology company focused on developing targeted therapies for patients with RAS-addicted cancers.

9. Atkore Inc. (NYSE:ATKR)

Atkore Inc. (NYSE:ATKR) is one of the 10 potential takeover targets with strong price momentum. The latest consequential step came on April 8, 2026, when Atkore announced the sale of its HDPE pipe and conduit business to Infra Pipes. The company said the deal was part of its ongoing strategic review process and would sharpen its focus on key electrical product offerings, targeted customers, and strategic markets, while also improving metrics such as adjusted EBITDA margin and return on invested capital.

That move fits a broader cleanup story that can make the company easier to value and potentially easier to buy. Atkore manufactures electrical products for commercial, industrial, data center, telecommunications, and solar applications, which gives it exposure to several parts of the electrification buildout. In its fiscal first-quarter 2026 results released on February 3, the company reported net sales of $655.5 million, down 0.9% year over year, while electrical segment sales rose 0.9% to $469.6 million. Management also said the earlier divestiture of the Tectron mechanical tube product line was another action taken as part of its broader review of strategic alternatives.

The takeover angle itself has been live for months. In November 2025, Reuters reported that Atkore’s board and management were considering options, including a sale or merger, after activist pressure. No buyer for the whole company has been publicly identified since then, but the strategic review and asset sales suggest the company is still reshaping itself in a way that could support a deal.

Atkore Inc. (NYSE:ATKR) manufactures electrical products for commercial, industrial, data center, telecommunications, and solar applications.